Colon cancer used to feel like a worry for later-something to think about decades down the road. Not anymore. An estimated ...

Bernstein lifted its Guardant Health price target to $200 after UnitedHealth's Shield coverage decision. Here's what it means ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Colon cancer is on the rise in younger people, which is why testing guidelines recommend testing starting at 45 for those at average risk. To stop colon cancer, it’s important to know when and how to ...

Time for a rear-ality check. Colorectal cancer rates have been rising among adults younger than 50 since the 1990s, a troubling trend that has perplexed scientists. Because of the increase in cases, ...

One analyst called the insurer’s decision a “watershed moment” for liquid biopsy-based cancer screening and for the category ...

Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. Colon cancer is a leading cause of cancer-related deaths.

Tens of millions of middle-aged and older Americans haven't gotten their recommended checks for early signs of potential colon cancer, either through the "gold standard" of colonoscopy or a ...

The American Cancer Society recently recommended that two blood tests can be an option for people who won't get a colonoscopy or do a stool test. No one looks forward to a colonoscopy, but for the ...

An investigational blood test for early detection of colorectal cancer (CRC) in average-risk adults met the primary endpoints of sensitivity and specificity in the PREEMPT CRC study, the largest study ...

As of July 1, Ontarians age 45 and up are eligible to receive the at-home fecal immunochemical screening test — or FIT — that detects traces of blood in the stool.